Key points are not available for this paper at this time.
Abstract Quantitative MRI biomarkers are increasingly requested in clinical practice in the management of patients with chronic liver diseases, to evaluate fibrosis, steatosis, iron overloard and liver function. The proton density fat fraction (PDFF) is a quantitative biomarker for the quantification of steatosis, being the current noninvasive reference standard for steatosis grading. R 2* is a biomarker of iron concentration and is bundled with PDFF. MR elastography measures liver stiffness through the quantification of mechanical waves generated by an external drive and it can be used to detect significant and advanced fibrosis. Hepatobiliary phase can provide information on residual liver function by quantitative or semiquantitative parameters. The functional liver imaging score is an emerging semiquantitative tool based on the three hepatobiliary phase features: liver parenchymal enhancement, biliary contrast excretion, and portal vein sign. This work discusses the role of quantitative MRI biomarkers, offering practical tips for the diagnosis of steatosis, iron, fibrosis and liver function.
Mazzola et al. (Wed,) studied this question.